



The Illinois Medical Bulletin



The Impact of High On-Treatment Platelet Reactivity on Cardiovascular Outcomes Following Percutaneous Coronary Intervention: A Review of the Evidence on Clopidogrel Response

¹A.Cole, ²A. Cueto-Dominguez

^{1,2} University of Illinois College of Medicine

Corresponding Email : doctorcole28948@gmail.com

Article History :

Received date : 2021/10/12
Revised date : 2021/11/28
Accepted date : 2021/12/09
Published date : 2022/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: The prevention of thrombotic complications after percutaneous coronary intervention (PCI) with stenting relies on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. Despite this standard of care, a subset of patients experiences recurrent ischemic events, suggesting a significant variability in individual response to therapy.

Literature Review: A review of the pivotal literature establishes the clinical importance of high on-treatment platelet reactivity (HTPR), a phenomenon often termed "clopidogrel resistance." A large body of prospective observational studies consistently and powerfully demonstrated that patients exhibiting HTPR, as measured by various platelet function assays, have a significantly higher risk of major adverse cardiovascular events, most notably the catastrophic complication of stent thrombosis. The primary mechanism underlying this variability was elucidated through landmark pharmacogenomic research. These studies identified that common loss-of-function genetic variants in the hepatic enzyme CYP2C19, which is essential for metabolizing clopidogrel into its active form, are a major determinant of HTPR and are strongly associated with an increased risk of adverse clinical outcomes.

Conclusion: The evidence reviewed confirms that HTPR is a critical, independent predictor of adverse ischemic events following PCI. This research established a clear phenotypic and genotypic basis for the variable efficacy of clopidogrel and created the foundational rationale for a personalized approach to antiplatelet therapy to overcome treatment resistance.

Keywords: Clopidogrel, Platelet Reactivity, Percutaneous Coronary Intervention (PCI), Stent Thrombosis, CYP2C19, Antiplatelet Therapy.

INTRODUCTION

Percutaneous coronary intervention (PCI) with the placement of intracoronary stents is a cornerstone of modern treatment for coronary artery disease. A critical component of this procedure is the prevention of stent thrombosis, a rare but often fatal complication caused by thrombus formation within the stent. The standard of care to prevent this is dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y₁₂ receptor inhibitor, with clopidogrel being the most widely used agent for this purpose for a significant period.

Despite the proven efficacy of DAPT, a notable number of patients continued to experience thrombotic events, including stent thrombosis and myocardial infarction. This clinical observation led to the hypothesis that there is significant inter-individual variability in the response to clopidogrel. This gave rise to the concept of high on-treatment platelet reactivity (HTPR), a laboratory-defined state of inadequate platelet inhibition despite adherence to clopidogrel therapy. This literature review will synthesise the pivotal scientific evidence that established HTPR as a major risk factor for adverse outcomes and uncovered its underlying genetic basis.

LITERATURE REVIEW

The understanding of clopidogrel's variable efficacy evolved from laboratory observation to a clinically validated risk factor with a defined genetic cause.

The scientific basis for the variability lies in the drug's complex pharmacology. Clopidogrel is a prodrug, meaning it is inactive when ingested and must be metabolized in the liver to its active form, which then irreversibly blocks the P2Y₁₂ receptor on platelets. This metabolic activation is a two-step process that is highly dependent on the function of several cytochrome P450 (CYP) enzymes. It was recognized that variations in the efficiency of this enzymatic

conversion could lead to significant differences in the amount of active drug generated and, consequently, in the level of platelet inhibition achieved by different individuals.

To quantify this variability, researchers utilized a number of laboratory and point-of-care platelet function assays. A series of large, prospective observational studies then used these assays to link the laboratory phenomenon of HTPR to clinical outcomes. These studies consistently and powerfully demonstrated that patients undergoing PCI who were identified as having HTPR after receiving a clopidogrel loading dose had a markedly higher incidence of subsequent major adverse cardiovascular events. The risk of stent thrombosis, in particular, was shown to be many times higher in these "non-responders" or "poor responders" compared to patients who exhibited an adequate antiplatelet response (Matetzky et al., 2004; Gurbel et al., 2003). HTPR was thus established as a strong, independent, and prognostically significant risk factor.

A major breakthrough in explaining the source of this variability came from the field of pharmacogenomics. Two large, landmark studies published concurrently provided a definitive genetic explanation. These studies investigated the role of common genetic variations (polymorphisms) in the genes for the CYP enzymes. They found that individuals who carried specific loss-of-function alleles for the *CYP2C19* gene were significantly less able to metabolize clopidogrel to its active form. This genetic status directly translated into higher levels of on-treatment platelet reactivity and, most importantly, a significantly increased risk of the composite endpoint of cardiovascular death, myocardial infarction, or stroke, with a particularly high risk of stent thrombosis (Mega et al., 2009; Simon et al., 2009).

This body of work—connecting the pharmacology, the phenotypic laboratory measurement, the clinical outcome, and the underlying genotype—provided a complete picture of the clopidogrel response phenomenon. It raised the critical clinical question of whether antiplatelet therapy should be personalized, either by routine platelet function testing or by genotyping, to identify poor responders who might benefit from alternative strategies, such as higher doses of clopidogrel or treatment with newer, more potent P2Y₁₂ inhibitors.

CONCLUSION

The pivotal literature on clopidogrel response fundamentally changed the understanding of dual antiplatelet therapy. It successfully transformed the concept of "clopidogrel resistance" from a

laboratory curiosity into a clinically critical and prognostically significant entity. The research provided unequivocal evidence that high on-treatment platelet reactivity is a powerful and independent predictor of thrombotic events after PCI with stenting.

Furthermore, the landmark discovery of the role of *CYP2C19* genetic polymorphisms provided a clear, actionable, and common biological cause for this variability in drug response. This body of evidence established a robust scientific foundation for the modern era of personalized antiplatelet therapy, underscoring the inadequacy of a "one-size-fits-all" approach and driving the development of strategies to ensure more consistent and effective platelet inhibition for all patients.

REFERENCES

Cuisset, T., Frere, C., Quilici, J., Morange, P.E., Nait-Saidi, L., Carvajal, J., Alessi, M.C. and Bonnet, J.L. (2007) 'High post-treatment platelet reactivity identified by a simple bedside assay is associated with a 10-fold risk of stent thrombosis after acute myocardial infarction', *Journal of Thrombosis and Haemostasis*, 5(12), pp. 2543-2545.

Gurbel, P.A., Bliden, K.P., Hiatt, B.L. and O'Connor, C.M. (2003) 'Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity', *Circulation*, 107(23), pp. 2908-2913.

Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Bienart, R., Goldenberg, I., Novikov, I., Pres, H., Savion, N., Varon, D. and Hod, H. (2004) 'Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction', *Circulation*, 109(25), pp. 3171-3175.

Mega, J.L., Close, S.L., Wiviott, S.D., Shen, L., Hockett, R.D., Brandt, J.T., Walker, J.R., Antman, E.M., Macias, W., Braunwald, E. and Sabatine, M.S. (2009) 'Cytochrome P-450 polymorphisms and response to clopidogrel', *New England Journal of Medicine*, 360(4), pp. 354-362.

Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P.G., Ferrières, J., Danchin, N. and Becquemont, L. (2009) 'Genetic determinants of response to clopidogrel and cardiovascular events', *New England Journal of Medicine*, 360(4), pp. 363-375.

